Addressing long-term PPI safety
- PMID: 32601032
- DOI: 10.1016/j.dld.2020.05.025
Addressing long-term PPI safety
Conflict of interest statement
Declaration of Competing Interest Carmelo Scarpignato has served as a speaker, consultant and/or advisory board member for Alfasigma, Pfizer, Takeda, Reckitt-Benkiser and Shionogi, and has in the past received funding from Giuliani Pharmaceuticals and Pfizer. Salvatore Tolone has no conflict of interest to disclose
Comment on
-
Latest insights into the hot question of proton pump inhibitor safety - a narrative review.Dig Liver Dis. 2020 Aug;52(8):842-852. doi: 10.1016/j.dld.2020.04.020. Epub 2020 Jun 6. Dig Liver Dis. 2020. PMID: 32513631 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
